Autolus Therapeutics plc
Autolus Therapeutics plc, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on developing innovative T cell therapies for cancer treatment. Founded in 2014, Autolus has rapidly established itself in the cell and gene therapy industry, with significant operational presence in Europe and the United States. The company is renowned for its proprietary technology platform, which enables the creation of next-generation T cell therapies designed to enhance patient outcomes. Autolus's lead product candidates, including AUTO1 and AUTO3, showcase unique mechanisms that target various malignancies, setting them apart in a competitive market. With a commitment to advancing cancer care, Autolus Therapeutics has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of immuno-oncology.
DitchCarbon Score
How does Autolus Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Autolus Therapeutics plc's score of 30 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Autolus Therapeutics plc's reported carbon emissions
In 2023, Autolus Therapeutics plc reported total carbon emissions of approximately 1,637,300 kg CO2e globally, comprising 2,800 kg CO2e from Scope 1, 917,600 kg CO2e from Scope 2, and 1,637,300 kg CO2e from Scope 3 emissions. This marks a significant increase in emissions compared to previous years, with 2022 emissions recorded at about 573,100 kg CO2e for Scope 3 alone. In 2021, the company reported total emissions of approximately 357,115 kg CO2e from Scope 3, alongside 9,613 kg CO2e from Scope 1 and 316,194 kg CO2e from Scope 2. The 2020 data indicated total emissions of 223,496 kg CO2e from Scope 3, 4,531 kg CO2e from Scope 1, and 221,727 kg CO2e from Scope 2. Despite the increase in emissions, Autolus has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests a need for enhanced climate commitments within the biopharmaceutical industry context. As a company headquartered in Great Britain, Autolus is positioned to align with broader UK climate goals, yet further transparency and action on emissions reduction would be beneficial.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 4,531 | 0,000 | 0,000 |
| Scope 2 | 221,727 | 000,000 | 000,000 |
| Scope 3 | 223,496 | 000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Autolus Therapeutics plc is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
